克拉斯
STK11段
医学
突变
癌症研究
癌症
肿瘤科
内科学
生物
结直肠癌
基因
遗传学
作者
Myriam Boeschen,Christina Katharina Kuhn,Hubert Wirtz,Hans-Jürgen Seyfarth,Armin Frille,Florian Lordick,Ulrich Hacker,Ulrike Obeck,Mathias Stiller,Hendrik Bläker,Maximilian von Laffert
出处
期刊:Lung Cancer
[Elsevier]
日期:2023-10-01
卷期号:184: 107361-107361
标识
DOI:10.1016/j.lungcan.2023.107361
摘要
Objectives Mutations in STK11 (STK11MUT) and KEAP1 (KEAP1MUT) occur frequently in non-small cell lung cancer (NSCLC) and are often co-mutated with KRAS. Several studies linked the co-occurrence of KRASMUT + STK11MUT, as well as KRASMUT + KEAP1MUT to reduced response to immune checkpoint inhibitors (ICI) and even a negative impact on survival. Data focusing STK11 + KEAP1 co-mutations or the triple mutation (KRAS + STK11 + KEAP1) are scarce. The recent availability of KRAS-G12C inhibitors increases the clinical relevance of those co-mutations in KRAS-mutated NSCLC. Materials and Methods We present a comprehensive bioinformatic analysis encompassing six datasets retrieved from cBioPortal. Results Independent of the treatment, triple mutations and STK11MUT + KEAP1MUT were significantly associated with a reduced overall survival (OS). Across treatments, OS of patients with a KRAS G12C triple mutation was significantly reduced compared to patients with KRAS G12C-only. Under ICI-therapy, there was no significant difference in OS between patients harboring the KRAS G12C-only and patients with the KRAS G12C triple mutation, but a significant difference between patients harboring KRAS non-G12C and KRAS non-G12C triple mutations. Triple mutated primary tumors showed a significantly increased frequency of distant metastases to bone and adrenal glands compared to KRAS-only mutated tumors. Additionally, our drug response analysis in cancer cell lines harboring the triple mutations revealed the WNT pathway inhibitor XAV-939 as a potential future drug candidate for this mutational situation. Conclusion The triple mutation status may serve as a negative prognostic and predictive factor across treatments compared to KRASMUT-only. KRAS G12C generally seems to be a negative predictive marker for ICI-therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI